China Pharma Holdings, Inc.

NYSEAM:CPHI Stock Report

Market Cap: US$3.4m

China Pharma Holdings Past Earnings Performance

Past criteria checks 0/6

China Pharma Holdings has been growing earnings at an average annual rate of 40.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 12.1% per year.

Key information

40.5%

Earnings growth rate

58.7%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-12.1%
Return on equity-72.7%
Net Margin-85.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How China Pharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSEAM:CPHI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246-520
30 Jun 246-420
31 Mar 246-420
31 Dec 237-320
30 Sep 238-320
30 Jun 238-320
31 Mar 238-330
31 Dec 228-430
30 Sep 228-430
30 Jun 228-430
31 Mar 229-430
31 Dec 2110-330
30 Sep 2110-431
30 Jun 2110-441
31 Mar 2111-341
31 Dec 2011-340
30 Sep 2011-2050
30 Jun 2011-2050
31 Mar 2010-2140
31 Dec 1911-2150
30 Sep 1911-1040
30 Jun 1911-1150
31 Mar 1912-1160
31 Dec 1812-1160
30 Sep 1813-1770
30 Jun 1814-1760
31 Mar 1814-1970
31 Dec 1713-1970
30 Sep 1715-970
30 Jun 1715-870
31 Mar 1715-970
31 Dec 1616-970
30 Sep 1615-12111
30 Jun 1616-781
31 Mar 1618-9101
31 Dec 1520-15161
30 Sep 1519-31281
30 Jun 1520-41351
31 Mar 1521-45403
31 Dec 1422-40363
30 Sep 1427-28233
30 Jun 1430-24233
31 Mar 1432-20202
31 Dec 1333-20162

Quality Earnings: CPHI is currently unprofitable.

Growing Profit Margin: CPHI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CPHI is unprofitable, but has reduced losses over the past 5 years at a rate of 40.5% per year.

Accelerating Growth: Unable to compare CPHI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CPHI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: CPHI has a negative Return on Equity (-72.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:15
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Pharma Holdings, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin DeGeeterLadenburg Thalmann & Company
Reni BenjaminRodman & Renshaw, LLC
Scott HenryRoth MKM